Brintellix® pharmacokinetic profile1
Brintellix® (vortioxetine) is indicated for the treatment of major depressive episodes in adults. Brintellix® is available at 10mg.†
Brintellix® pharmacokinetic profile1
A dose adjustment of Brintellix® may be considered in patients who concomitantly use a broad cytochrome P450 inducer (e.g. rifampicin, carbamazepine, phenytoin) or a strong CYP2D6 inhibitor (e.g. bupropion, quinidine, fluoxetine, paroxetine). Concomitant use of Brintellix® with non-selective monoamine oxidase inhibitors (MAOIs or selective MAO-A inhibitors) is contraindicated.1,2
A dose adjustment of Brintellix® may be considered in patients who concomitantly use a broad cytochrome P450 inducer (e.g. rifampicin, carbamazepine, phenytoin) or a strong CYP2D6 inhibitor (e.g. bupropion, quinidine, fluoxetine, paroxetine). Concomitant use of Brintellix® with non-selective monoamine oxidase inhibitors (MAOIs or selective MAO-A inhibitors) is contraindicated.1,2
† The Brintellix® starting and recommended dose of 10 mg may be increased up to 20 mg or decreased to 5 mg depending on patients’ individual response. For patients aged ≥65 years, a starting dose of 5 mg/day should be used.1
Abbreviations:
Cmax, maximum concentration; Tmax, time to peak drug concentration.
† The Brintellix® starting and recommended dose of 10 mg may be increased up to 20 mg or decreased to 5 mg depending on patients’ individual response. For patients aged ≥65 years, a starting dose of 5 mg/day should be used.1
Abbreviations:
Cmax, maximum concentration; Tmax, time to peak drug concentration.